Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Carcinoma, Non-small-Cell Lung
Clinical trial register · United States · industry-sponsored

Carcinoma, Non-small-Cell Lung Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 44 Florida 34 Massachusetts 25 New York 22 Illinois 21
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC12 Merck Sharp & Dohme LLC6 Seagen, a wholly owned subsidiary of Pfizer6 Eli Lilly and Company6 AstraZeneca5
State
California44 Florida34 Massachusetts25 New York22 Illinois21
All 40 states
Target enrolment
to

Carcinoma, Non-small-Cell Lung trials in the USA

62 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Janssen Research & Development, LLC
Phase 2
68
California, Oregon
2026-07-28
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
Janssen Research & Development, LLC
Phase 1/2
60
New York, Virginia
2026-03-03
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Recruiting
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2
96
Kentucky, Maryland, Pennsylvania
2025-05-13
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
Recruiting
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
A Study of DM005 in Patients With Advanced Solid Tumors
NCT06515990Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Phase 1/2
208
Michigan, Texas, Virginia
2024-10-31
Active, closed
A Study of DM001 in Patients With Advanced Solid Tumors
NCT06475937Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1
128
Tennessee, Texas
2024-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Active, closed
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsSofe-M·Itraconazole·Bevacizumab·Carboplatin
Eli Lilly and Company
Phase 1
575
Arizona, California, Georgia, Michigan, New York, Ohio, Texas, Utah
2024-05-20
Active, closed
AstraZeneca
Phase 2
103
California, District of Columbia, Florida, Georgia, Hawaii, Illinois, Maryland, Massachusetts
2024-04-04
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Arizona, California, Georgia, Illinois, Missouri, Nevada, New Jersey, New York
2024-02-16
Recruiting
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Iowa, Massachusetts, New York, Washington
2023-12-21
Active, closed
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2023-11-20
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2023-11-14
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
California, Oregon, Texas, Virginia
2023-05-18
Active, closed
Janssen Research & Development, LLC
Phase 2
68
California, Virginia, Washington
2023-05-18
Recruiting
Lantern Pharma Inc.
Phase 2
90
California, Pennsylvania, Texas, Virginia
2023-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Alabama, California, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2023-02-06
Recruiting
MYLUNG Consortium Part 3: Observational Study
NCT05885698Carcinoma, Non-Small-Cell Lung
US Oncology Research
Observational
7,500
Alabama, Arizona, Colorado, Florida, Illinois, Maryland, Minnesota, New York
2023-01-30
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2022-12-21
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Alabama, California, New York, Virginia
2022-12-13
Recruiting
Janssen Research & Development, LLC
Phase 2
520
California, District of Columbia, Florida, Kansas, Maryland, Massachusetts, Missouri, New Jersey
2022-11-11
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Massachusetts, New York, Pennsylvania, Tennessee
2022-10-26
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Alabama, California, Iowa, Michigan, Ohio, Texas, Utah, Virginia
2022-10-25
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Massachusetts, New York
2022-10-24
Active, closed
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944Carcinoma, Non-Small-Cell Lung
DrugsThiotepa·Cemiplimab
Maia Biotechnology
Phase 2
227
Alabama, New Jersey
2022-06-08
Active, closed
Eli Lilly and Company
Phase 3
152
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Tennessee, Texas
2021-12-20
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Alabama, Arizona, California, Colorado, Florida, Georgia, Mississippi, Nebraska
2021-11-17
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugSabestomig
AstraZeneca
Phase 1/2
136
Georgia, Indiana, New York, Tennessee
2021-09-28
Recruiting
Genprex, Inc.
Phase 1/2
158
California, Colorado, Illinois, Kentucky, Maryland, New Jersey, Ohio, Texas
2021-09-03
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed
Eli Lilly and Company
Phase 1/2
540
Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire
2021-07-19
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Georgia, Massachusetts, Pennsylvania, Texas
2021-02-24
Active, closed
MYLUNG Consortium Study Protocol 2
NCT05644808Carcinoma, Non-Small-Cell Lung
US Oncology Research
Observational
1,002
Alabama, Colorado, Florida, Illinois, Maryland, Minnesota, New York, Ohio
2020-12-29
Active, closed
Janssen Research & Development, LLC
Phase 3
308
California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey, New York
2020-10-13
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2020-09-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Alabama, Arkansas, California, Florida, Indiana, Kentucky, Massachusetts, Michigan
2020-07-06
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kansas, Massachusetts
2020-06-08
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
450
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Recruiting
Merck Sharp & Dohme LLC
Observational
1,065
Arizona, California, District of Columbia, Kentucky, Maryland, Massachusetts, Nebraska, New Hampshire
2019-12-19
Active, closed
Bristol-Myers Squibb
Phase 3
461
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Hampshire, Ohio
2019-11-05
Active, closed
Janssen Research & Development, LLC
Phase 1
701
California, Florida, Massachusetts, Michigan, Missouri, New York, Oregon, Pennsylvania
2019-09-04
By invitation
Development and Analysis of a Stool Bank for Cancer Patients
NCT04291755Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal
DrugsIpilimumab·Nivolumab·Pembrolizumab
Persephone Biosciences
Observational
100
California, Florida
2019-06-28
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Massachusetts, Tennessee
2019-05-07
Active, closed
AstraZeneca
Phase 3
724
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Georgia, Illinois
2019-03-06
Active, closed
Hoffmann-La Roche
Phase 3
257
Illinois, Massachusetts, Pennsylvania
2018-08-16
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2018-06-25
Active, closed
MedImmune LLC
Phase 1/2
43
California, Colorado, Connecticut, Georgia, Illinois, Maryland, New York, Texas
2018-05-08
Active, closed
Pfizer
Phase 3
296
Florida, Massachusetts, New York, Tennessee, Washington
2017-04-27
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
DrugMobocertinib
Takeda
Phase 1/2
334
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2016-06-16
Rows per page Showing 1–62 of 62
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/carcinoma-non-small-cell-lung

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 62 of those studies listing the condition Carcinoma, Non-small-Cell Lung.

How many Carcinoma, Non-small-Cell Lung trials are recruiting in the US?

27 of the 62 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 34 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Carcinoma, Non-small-Cell Lung), 62 studies
PhaseStudiesRecruitingShare
Phase 319730.6%
Phase 214822.6%
Phase 1/213521%
Phase 112519.4%
Observational426.5%

Most active sponsors

Lead sponsors with the most studies (Carcinoma, Non-small-Cell Lung)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC124
Eli Lilly and Company64
Merck Sharp & Dohme LLC64
Seagen, a wholly owned subsidiary of Pfizer63
AstraZeneca51
Pfizer53
Novartis Pharmaceuticals40
Bristol-Myers Squibb31
Johnson & Johnson Enterprise Innovation Inc.21
US Oncology Research21

Top states

Top states (Carcinoma, Non-small-Cell Lung), by number of studies with a site there
StateStudies
California44
Florida34
Massachusetts25
New York22
Illinois21
Georgia20
Colorado18
Arizona17
Alabama16
Maryland15
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.